These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7939425)

  • 61. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels.
    Yamamoto C; Enomoto N; Kurosaki M; Yu SH; Tazawa J; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Dec; 26(6):1616-20. PubMed ID: 9398006
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan.
    Akhtar N; Bilal M; Rizwan M; Khan MA; Khan A
    Asian Pac J Cancer Prev; 2015; 16(3):1037-40. PubMed ID: 25735327
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
    Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
    Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The changes in quantitative HCV RNA titers during interferon alpha 2B therapy in patients with chronic hepatitis C infection.
    Tong MJ; Blatt LM; Conrad A; Hur Y; Russell J; El-Farra NS; Co RL
    Am J Gastroenterol; 1998 Apr; 93(4):601-5. PubMed ID: 9576455
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level.
    Yamada G; Takatani M; Kishi F; Takahashi M; Doi T; Tsuji T; Shin S; Tanno M; Urdea MS; Kolberg JA
    Hepatology; 1995 Nov; 22(5):1351-4. PubMed ID: 7590646
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alpha therapy in chronic hepatitis C patients.
    Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S; Orito E; Mizokami M
    J Med Virol; 1996 Apr; 48(4):354-9. PubMed ID: 8699168
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis.
    Furusyo N; Hayashi J; Ueno K; Sawayama Y; Kawakami Y; Kishihara Y; Kashiwagi S
    Clin Ther; 1997; 19(6):1352-67. PubMed ID: 9444445
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quantification and genotyping of serum HCV-RNA in patients with chronic hepatitis C undergoing interferon treatment.
    Gerken G; Knolle P; Jakobs S; Meyer zum Büschenfelde KH
    Arch Virol; 1997; 142(3):459-64. PubMed ID: 9349292
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative assessment of hepatitis C virus RNA in peripheral blood mononuclear cells during therapy with interferon-alpha2a.
    Moonka DK; Henzel BS; Gutekunst K; O'Brien CB
    J Viral Hepat; 1998 Jan; 5(1):27-33. PubMed ID: 9493514
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
    Shiffman ML; Suter F; Bacon BR; Nelson D; Harley H; Solá R; Shafran SD; Barange K; Lin A; Soman A; Zeuzem S;
    N Engl J Med; 2007 Jul; 357(2):124-34. PubMed ID: 17625124
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
    Lin R; Roach E; Zimmerman M; Strasser S; Farrell GC
    J Hepatol; 1995 Nov; 23(5):487-96. PubMed ID: 8583134
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Serological and salivary markers compared with biochemical markers for monitoring interferon treatment for hepatitis C virus infection.
    Roy KM; Bagg J; Bird GL; Spence E; Follett EA; Mills PR; Lau JY
    J Med Virol; 1995 Dec; 47(4):429-34. PubMed ID: 8636714
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
    Zeuzem S; Rodríguez-Torres M; Rajender Reddy K; Marcellin P; Diago M; Craxi A; Pockros P; Rizzetto M; Bernstein D; Shiffman ML; Lin A; Tatsch F; Hadziyannis S
    J Viral Hepat; 2012 Nov; 19(11):766-74. PubMed ID: 23043383
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Serial density analysis of hepatitis C virus particle populations in chronic hepatitis C patients treated with interferon-alpha.
    Kanto T; Hayashi N; Takehara T; Hagiwara H; Mita E; Oshita M; Katayama K; Kasahara A; Fusamoto H; Kamada T
    J Med Virol; 1995 Jul; 46(3):230-7. PubMed ID: 7561795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.